Literature DB >> 21062932

Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment.

D Ross Camidge1, Scott A Kono, Antonella Flacco, Aik-Choon Tan, Robert C Doebele, Qing Zhou, Lucio Crino, Wilbur A Franklin, Marileila Varella-Garcia.   

Abstract

PURPOSE: Anaplastic lymphoma kinase (ALK) rearrangements, associated with sensitivity to an experimental ALK/MET inhibitor, occur in 3% to 5% of non-small cell lung cancers. Intratumoral fluorescence in situ hybridization (FISH) heterogeneity has been reported. We explored the heterogeneity basis, the requirements for accurately determining ALK FISH positivity, and the effect of enriching the tested population using clinical and molecular factors. EXPERIMENTAL
DESIGN: Lung cancer patients were screened by ALK and MET FISH and for EGFR and KRAS mutations.
RESULTS: Thirteen ALK-positive cases were identified from 73 screened patients. Gene copy number increases occurred together with classic rearrangements. All positive cases were adenocarcinomas, 12 were EGFR/KRAS wild-type, and 1 had a coexistent EGFR exon 20 mutation. No association with MET amplification occurred. ALK positivity was associated with <10-pack-year smoking status (P = 0.0004). Among adenocarcinomas, without KRAS or EGFR mutations, with <10-pack-year history, 44.8% of cases were ALK positive. ALK FISH positivity was heterogeneous, but mean values in tumor areas from ALK-positive patients (54% of cells; range, 22-87%) were significantly higher than in adjacent normal tissue or tumor/normal areas from ALK-negative patients (mean, 5-7%). Contiguous sliding field analyses showed diffuse heterogeneity without evidence of focal ALK rearrangements. One hundred percent sensitivity and specificity occurred when four or more fields (∼60 cells) were counted.
CONCLUSIONS: Intratumoral ALK FISH heterogeneity reflects technique, not biology. The clinical activity of ALK/MET inhibitors in ALK-positive patients probably reflects ALK, but not MET, activity. Prescreening by histology, EGFR/KRAS mutations, and smoking status dramatically increases the ALK-positive hit rate compared with unselected series. ©2010 AACR.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21062932      PMCID: PMC3395226          DOI: 10.1158/1078-0432.CCR-10-0851

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  25 in total

Review 1.  Lung cancer.

Authors:  Roy S Herbst; John V Heymach; Scott M Lippman
Journal:  N Engl J Med       Date:  2008-09-25       Impact factor: 91.245

2.  EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer.

Authors:  Jussi P Koivunen; Craig Mermel; Kreshnik Zejnullahu; Carly Murphy; Eugene Lifshits; Alison J Holmes; Hwan Geun Choi; Jhingook Kim; Derek Chiang; Roman Thomas; Jinseon Lee; William G Richards; David J Sugarbaker; Christopher Ducko; Neal Lindeman; J Paul Marcoux; Jeffrey A Engelman; Nathanael S Gray; Charles Lee; Matthew Meyerson; Pasi A Jänne
Journal:  Clin Cancer Res       Date:  2008-07-01       Impact factor: 12.531

3.  Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC.

Authors:  Alexa B Turke; Kreshnik Zejnullahu; Yi-Long Wu; Youngchul Song; Dora Dias-Santagata; Eugene Lifshits; Luca Toschi; Andrew Rogers; Tony Mok; Lecia Sequist; Neal I Lindeman; Carly Murphy; Sara Akhavanfard; Beow Y Yeap; Yun Xiao; Marzia Capelletti; A John Iafrate; Charles Lee; James G Christensen; Jeffrey A Engelman; Pasi A Jänne
Journal:  Cancer Cell       Date:  2010-01-19       Impact factor: 31.743

4.  Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors.

Authors:  Ultan McDermott; A John Iafrate; Nathanael S Gray; Toshi Shioda; Marie Classon; Shyamala Maheswaran; Wenjun Zhou; Hwan Geun Choi; Shannon L Smith; Lori Dowell; Lindsey E Ulkus; Georgiana Kuhlmann; Patricia Greninger; James G Christensen; Daniel A Haber; Jeffrey Settleman
Journal:  Cancer Res       Date:  2008-05-01       Impact factor: 12.701

5.  Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer.

Authors:  Young Lim Choi; Kengo Takeuchi; Manabu Soda; Kentaro Inamura; Yuki Togashi; Satoko Hatano; Munehiro Enomoto; Toru Hamada; Hidenori Haruta; Hideki Watanabe; Kentaro Kurashina; Hisashi Hatanaka; Toshihide Ueno; Shuji Takada; Yoshihiro Yamashita; Yukihiko Sugiyama; Yuichi Ishikawa; Hiroyuki Mano
Journal:  Cancer Res       Date:  2008-07-01       Impact factor: 12.701

Review 6.  Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.

Authors:  Jeffrey A Engelman; Pasi A Jänne
Journal:  Clin Cancer Res       Date:  2008-05-15       Impact factor: 12.531

7.  Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts.

Authors:  Kengo Takeuchi; Young Lim Choi; Manabu Soda; Kentaro Inamura; Yuki Togashi; Satoko Hatano; Munehiro Enomoto; Shuji Takada; Yoshihiro Yamashita; Yukitoshi Satoh; Sakae Okumura; Ken Nakagawa; Yuichi Ishikawa; Hiroyuki Mano
Journal:  Clin Cancer Res       Date:  2008-10-15       Impact factor: 12.531

8.  Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.

Authors:  Manabu Soda; Young Lim Choi; Munehiro Enomoto; Shuji Takada; Yoshihiro Yamashita; Shunpei Ishikawa; Shin-ichiro Fujiwara; Hideki Watanabe; Kentaro Kurashina; Hisashi Hatanaka; Masashi Bando; Shoji Ohno; Yuichi Ishikawa; Hiroyuki Aburatani; Toshiro Niki; Yasunori Sohara; Yukihiko Sugiyama; Hiroyuki Mano
Journal:  Nature       Date:  2007-07-11       Impact factor: 49.962

9.  EML4-ALK fusion lung cancer: a rare acquired event.

Authors:  Sven Perner; Patrick L Wagner; Francesca Demichelis; Rohit Mehra; Christopher J Lafargue; Benjamin J Moss; Stefanie Arbogast; Alex Soltermann; Walter Weder; Thomas J Giordano; David G Beer; David S Rickman; Arul M Chinnaiyan; Holger Moch; Mark A Rubin
Journal:  Neoplasia       Date:  2008-03       Impact factor: 5.715

10.  Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer.

Authors:  Klarisa Rikova; Ailan Guo; Qingfu Zeng; Anthony Possemato; Jian Yu; Herbert Haack; Julie Nardone; Kimberly Lee; Cynthia Reeves; Yu Li; Yerong Hu; Zhiping Tan; Matthew Stokes; Laura Sullivan; Jeffrey Mitchell; Randy Wetzel; Joan Macneill; Jian Min Ren; Jin Yuan; Corey E Bakalarski; Judit Villen; Jon M Kornhauser; Bradley Smith; Daiqiang Li; Xinmin Zhou; Steven P Gygi; Ting-Lei Gu; Roberto D Polakiewicz; John Rush; Michael J Comb
Journal:  Cell       Date:  2007-12-14       Impact factor: 41.582

View more
  106 in total

1.  Why technical aspects rather than biology explain cellular heterogeneity in ALK-positive non-small cell lung cancer.

Authors:  Anne McLeer-Florin; Sylvie Lantuéjoul
Journal:  J Thorac Dis       Date:  2012-06-01       Impact factor: 2.895

2.  Native and rearranged ALK copy number and rearranged cell count in non-small cell lung cancer: implications for ALK inhibitor therapy.

Authors:  D Ross Camidge; Margaret Skokan; Porntip Kiatsimkul; Barbara Helfrich; Xian Lu; Anna E Barón; Nathan Schulte; DeLee Maxson; Dara L Aisner; Wilbur A Franklin; Robert C Doebele; Marileila Varella-Garcia
Journal:  Cancer       Date:  2013-09-10       Impact factor: 6.860

3.  Oncogene status predicts patterns of metastatic spread in treatment-naive nonsmall cell lung cancer.

Authors:  Robert C Doebele; Xian Lu; Christopher Sumey; Delee A Maxson; Andrew J Weickhardt; Ana B Oton; Paul A Bunn; Anna E Barón; Wilbur A Franklin; Dara L Aisner; Marileila Varella-Garcia; D Ross Camidge
Journal:  Cancer       Date:  2012-01-26       Impact factor: 6.860

4.  Correlations between the percentage of tumor cells showing an anaplastic lymphoma kinase (ALK) gene rearrangement, ALK signal copy number, and response to crizotinib therapy in ALK fluorescence in situ hybridization-positive nonsmall cell lung cancer.

Authors:  D Ross Camidge; Mariana Theodoro; Delee A Maxson; Margaret Skokan; Tara O'Brien; Xian Lu; Robert C Doebele; Anna E Barón; Marileila Varella-Garcia
Journal:  Cancer       Date:  2012-01-26       Impact factor: 6.860

Review 5.  The pivotal role of pathology in the management of lung cancer.

Authors:  Morgan R Davidson; Adi F Gazdar; Belinda E Clarke
Journal:  J Thorac Dis       Date:  2013-10       Impact factor: 2.895

Review 6.  ALK alterations and inhibition in lung cancer.

Authors:  Tri Le; David E Gerber
Journal:  Semin Cancer Biol       Date:  2016-09-13       Impact factor: 15.707

Review 7.  New strategies for treatment of ALK-rearranged non-small cell lung cancers.

Authors:  Takaaki Sasaki; Pasi A Jänne
Journal:  Clin Cancer Res       Date:  2011-10-18       Impact factor: 12.531

Review 8.  Lung cancer as a paradigm for precision oncology in solid tumours.

Authors:  Simon Schallenberg; Sabine Merkelbach-Bruse; Reinhard Buettner
Journal:  Virchows Arch       Date:  2017-07-20       Impact factor: 4.064

Review 9.  ALK and crizotinib: after the honeymoon…what else? Resistance mechanisms and new therapies to overcome it.

Authors:  Christian Rolfo; Francesco Passiglia; Marta Castiglia; Luis E Raez; Paul Germonpre; Ignacio Gil-Bazo; Karen Zwaenepoel; Annemieke De Wilde; Giuseppe Bronte; Antonio Russo; Jan P Van Meerbeeck; Paul Van Schil; Patrick Pauwels
Journal:  Transl Lung Cancer Res       Date:  2014-08

Review 10.  ALK inhibitors: a new targeted therapy in the treatment of advanced NSCLC.

Authors:  Francesca Casaluce; Assunta Sgambato; Paolo Maione; Antonio Rossi; Carmine Ferrara; Alba Napolitano; Giovanni Palazzolo; Fortunato Ciardiello; Cesare Gridelli
Journal:  Target Oncol       Date:  2013-01-17       Impact factor: 4.493

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.